Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by XTX Topco Ltd

XTX Topco Ltd grew its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 177.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,205 shares of the company’s stock after purchasing an additional 7,173 shares during the quarter. XTX Topco Ltd’s holdings in Axsome Therapeutics were worth $902,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AXSM. EntryPoint Capital LLC acquired a new stake in Axsome Therapeutics during the 1st quarter worth $35,000. Russell Investments Group Ltd. boosted its stake in Axsome Therapeutics by 5,550.0% during the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock worth $63,000 after purchasing an additional 777 shares during the last quarter. Covestor Ltd boosted its stake in Axsome Therapeutics by 54,750.0% during the 1st quarter. Covestor Ltd now owns 1,097 shares of the company’s stock worth $88,000 after purchasing an additional 1,095 shares during the last quarter. Janiczek Wealth Management LLC acquired a new stake in Axsome Therapeutics during the 1st quarter worth $97,000. Finally, Natixis boosted its stake in Axsome Therapeutics by 13.6% during the 1st quarter. Natixis now owns 1,235 shares of the company’s stock worth $99,000 after purchasing an additional 148 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Up 1.6 %

Shares of AXSM opened at $95.84 on Friday. The firm has a market cap of $4.55 billion, a P/E ratio of -15.02 and a beta of 1.25. Axsome Therapeutics, Inc. has a 12-month low of $55.02 and a 12-month high of $98.40. The company’s 50-day moving average price is $87.93 and its 200 day moving average price is $79.62. The company has a current ratio of 2.48, a quick ratio of 2.40 and a debt-to-equity ratio of 1.77.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.06. The company had revenue of $87.17 million for the quarter, compared to analyst estimates of $84.53 million. Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%. On average, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -4.73 earnings per share for the current year.

Insiders Place Their Bets

In other Axsome Therapeutics news, Director Mark E. Saad sold 11,016 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the sale, the director now directly owns 10,002 shares in the company, valued at $913,282.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Axsome Therapeutics news, COO Mark L. Jacobson sold 47,739 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at $487,275.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark E. Saad sold 11,016 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the sale, the director now owns 10,002 shares in the company, valued at $913,282.62. The disclosure for this sale can be found here. Insiders own 22.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Royal Bank of Canada lowered their target price on shares of Axsome Therapeutics from $131.00 to $130.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. UBS Group lowered their price target on shares of Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Bank of America raised shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $95.00 to $106.00 in a research report on Tuesday, August 6th. Wells Fargo & Company assumed coverage on shares of Axsome Therapeutics in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research report on Thursday, September 5th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $124.57.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.